Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Death Risk Drops by 50% for Diabetes Patients Using Statins

Type 2 diabetes patients on statin drugs have lower mortality risk....

Advertisement

In randomized clinical trials, involving 5,152 men and women from 66 to 96 years of age statin medications have been shown to reduce the risk of death in people with type 2 diabetes.

Vilmundur Gudnason, MD, PhD, of the University of Iceland, and colleagues wanted to see if statins had the same beneficial effect in observational studies on older people with type 2 diabetes.

They found that type 2 diabetes patients taking statin drugs had a 50 percent lower risk of dying from heart-related causes and a 53 percent lower risk of dying from all causes, compared to those not taking statins.

Among those without diabetes, statin use was associated with 16 percent lower risk of heart-related death and a 30 percent lower risk of death from all causes.

Diabetes patients who used statins had a similar risk of death as the general population without diabetes. In other words, statin use lowered the risk of death to normal levels, rather than the increased risk generally associated with diabetes.

According to the authors, this observational study adds to a body of evidence showing that statin use may be beneficial for people with type 2 diabetes.

The results urgently call for other population-based studies with comparable information to confirm the effect of statin use on death risk in individuals with type 2 diabetes.

BMJ Open August 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Past five issues: Issue 753 | Diabetes Clinical Mastery Series Issue 212 | GLP-1 Special Editions October 2014 | Issue 752 | SGLT-2 Inhibitors Special Edition October 2014 |

2014 Most Popular Articles:

For Your Patients: Why Daily Movement Improves Your Brain Health (Part 2): Brain Hormone Changes
Posted October 17, 2014
Adding an SGLT2 to Insulin Improved Control
Posted October 17, 2014
Two Positive Phase 3 Trials for ITCA 650, a GLP-1 Agonist, in Type 2 Diabetes
Posted October 10, 2014
Vitamin D and Type 2 Diabetes Risk
Posted October 17, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
SGLT-2 Inhibitor May Reduce Blood Pressure for Type 2s
Posted October 17, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will the performance of the Affordable Healthcare Act affect your vote for the election?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control